Cryoport Inc - CYRX STOCK NEWS

DHL Group has announced the acquisition of CRYOPDP from Cryoport, Inc. (NASDAQ: CYRX), marking a significant expansion in specialized pharma logistics. CRYOPDP, operating in 15 countries and handling over 600,000 shipments annually across 135 countries, specializes in clinical trials, biopharma, and cell & gene therapy logistics.

The acquisition strengthens DHL's Life Sciences and Healthcare business, which generated over EUR 5 billion in global revenue in 2024. As part of the deal, DHL and Cryoport will form a strategic partnership to enhance their supply chain service offerings in the global life sciences sector.

This strategic move aligns with DHL Group's Strategy 2030, focusing on temperature-controlled networks and specialty courier coverage. The partnership aims to leverage DHL's global logistics capabilities with Cryoport's specialized solutions, particularly expanding their reach in APAC and EMEA regions.

Cryoport (Nasdaq: CYRX), a leading global supply chain solutions provider for the life sciences industry, has announced an investor call scheduled for March 31, 2025, at 8:30 a.m. ET. The call will focus on discussing the company's recent strategic partnership with DHL Group and DHL's acquisition of CRYOPDP.

The conference call will feature management team presentations followed by a Q&A session addressing investor inquiries about these developments. A slide deck will accompany the presentation.

The recorded call will be available approximately three hours after completion in the Investor Relations section at www.cryoportinc.com. A dial-in replay will be accessible until April 7, 2025, via:

• United States: 1-844-512-2921
• International: 1-412-317-6671
• Replay entry code: 1197941#

Cryoport (NASDAQ: CYRX) has announced the launch of MVE Biological Solutions' High-Efficiency 800 C (HE 800 C), a new cryogenic freezer designed for fertility clinics, biorepositories, and clinical laboratories. The device offers ultra-cold storage at -190°C with a capacity to store over 22,000 ½cc straws in a compact, space-efficient design.

The HE 800 C features compatibility with SUC-1 inventory management systems for streamlined sample organization and retrieval. The freezer combines ergonomic features for easier sample handling, reducing strain on laboratory personnel while maintaining consistent performance in preserving sensitive biological materials.

Cryoport (NASDAQ: CYRX) reported its Q4 and FY 2024 financial results, achieving full-year revenue of $228.4 million, aligned with guidance. The company's Commercial Cell & Gene Therapy revenue grew 20% year-over-year to $26 million in FY 2024.

Key highlights include supporting 701 global clinical trials, improved gross margin to 45.8% in Q4 2024 (up from 40.6% in Q4 2023), and BioStorage/BioServices revenue growth of 11% in FY 2024. The company added five new approved therapies in 2024, bringing their total commercial therapy count to 19.

Financial results show a net loss of $114.8 million for FY 2024, with negative adjusted EBITDA of $15.1 million. The company maintains a strong cash position of $261.7 million and has provided 2025 revenue guidance of $240-250 million.

Cryoport Inc (Nasdaq: CYRX) has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 4, 2025, after U.S. markets close. The company will release a comprehensive document titled 'Cryoport Fourth Quarter and Full Year 2024 in Review' at 4:05 p.m. ET, providing financial and operational performance details.

Management will host a Q&A conference call at 5:00 p.m. ET the same day, accompanied by a slide deck. The call will be accessible via U.S. dial-in (1-800-717-1738) and International dial-in (1-646-307-1865) with Conference ID 1116296. A webcast replay will be available for a time, and a dial-in replay will be accessible until March 11, 2025.

Cryoport (NASDAQ: CYRX) has unveiled its new Cryoport Express® Cryogenic HV3 Shipping System, designed for transporting biologics and temperature-sensitive materials. The HV3's innovative features include a rectilinear design that eliminates palletization needs, enabling transport on narrow-bodied aircraft and reducing flight rejections.

The system maintains temperatures at -150°C or lower and includes enhanced payload protection, additional space for accessories, and improved storage efficiency through stacking capabilities. Key features include integrated condition monitoring, robust wheels, and front-facing handles for better point-of-care accessibility.

The HV3 is compatible with Cryoport's Safepak® System and will be showcased at Phacilitate's Advanced Therapies Week in Dallas. The innovation aims to improve patient access to vital cell therapies in smaller cities and remote areas by increasing available shipping lanes and ensuring compliance with regional carriers.

Moffitt Cancer Center and Cryoport (NASDAQ: CYRX) announced a strategic collaboration where Cryoport's CRYOGENE will provide state-of-the-art biorepository services at Moffitt's Speros FL campus in Pasco County, Florida. The collaboration aims to support the development of cell and gene therapies, with the industry projected to reach over $97 billion by 2033 at an 18.3% CAGR from 2024-2033.

The facility will be located adjacent to Moffitt's 250,000-square-foot Discovery & Innovation Center and will enhance collaboration across Moffitt's expanding health system. CRYOGENE, which currently manages over 25 million samples across its Texas locations, will provide biostorage technologies and logistics services to support patient treatments and medical research.

This partnership is part of Speros' master development plan, which includes multiple phases focusing on cell and gene therapies, AI, biotech, and other life sciences initiatives. Construction of Moffitt's outpatient and proton therapy center began in 2023, with completion scheduled for 2026.

Cryoport (NASDAQ: CYRX) announced that its subsidiary MVE Biological Solutions has successfully registered all three manufacturing facilities with the FDA. The facilities are located in Ball Ground, Georgia; New Prague, Minnesota; and Chengdu, China. Additionally, all applicable MVE-manufactured cryogenic freezers and dewars are now FDA-listed.

The registration requires adherence to stringent requirements, including 21 CFR Part 820 and Good Manufacturing Practices (GMP). This FDA registration and product listing complements MVE's existing ISO 13485 certification. MVE is a leading global manufacturer of high-quality cryogenic freezers and dewars.

Cryoport (Nasdaq: CYRX) announced the opening of its new IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium. The ~1,300 square meter GMP-compliant cryopreservation facility can process over 1,100 leukapheresis products annually. The Center of Excellence will provide standardized bioprocessing, cryopreservation, and distribution solutions for cell therapy manufacturing, focusing on leukapheresis starting materials. The facility will serve as Cryoport Systems' European Center of Excellence, transferring optimized cryopreservation processes to other Cryoport facilities to ensure consistent quality across clinical and commercial cell-based therapy programs.